Equibles does not estimate personal net worth.
Get an email with a short summary when Regeneron Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get REGN alertsLeonard Schleifer is recorded as CEO at Regeneron Pharmaceuticals, Inc. (REGN). The proxy statement of Regeneron Pharmaceuticals, Inc. reports total compensation of $6,823,034 for Leonard Schleifer in fiscal 2024, including a base salary of $1,941,100. Disclosed compensation is on record for 8 fiscal years. Leonard Schleifer has spoken on 22 earnings calls and 1 other investor event across 1 company, most recently for Regeneron Pharmaceuticals, Inc. on October 30, 2026. Regeneron Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Regeneron Pharmaceuticals, Inc. includes George D. Yancopoulos, M.D., Ph.D. (Chairman), Leonard S. Schleifer, M.D., Ph.D. (Chairman), Joseph J. LaRosa (General Counsel) and 7 others.
“We're pleased to report another quarter of strong performance driven by outstanding commercial execution and a large and diverse pipeline that is continuing to deliver on its promise.”
“It's an exciting day for Regeneron and Sanofi as we extend our highly successful collaboration by adding differentiated assets that have the potential to address type 2 inflammatory diseases.”
“Regeneron capped 2025 with another solid quarter of commercial execution with fourth quarter total revenue up 3% year-over-year, driven by double-digit net sales growth for three of our leading products.”
“For my remarks today, I will summarize our third quarter top line performance, provide an update on EYLEA HD regulatory matters, briefly discuss our recent pipeline progress, and close with some comments regarding our discussions with the United States government to lower drug costs for American patients while…”
“For my remarks today, I will review some of our key performance drivers from the second quarter, then briefly discuss some pipeline advances we have made this year and close with some comments on our capital allocation principles.”
Biotechnology · Healthcare
CEO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Regeneron Pharmaceuticals, Inc. (REGN) | M.D., Ph.D. Board co-Chair, President and Chief Executive Officer | $1,941,100 | $6,823,034 |
| 2023 | Regeneron Pharmaceuticals, Inc. (REGN) | M.D., Ph.D. Board co-Chair, President and Chief Executive Officer | $1,875,415 | $8,184,338 |
| 2022 | Regeneron Pharmaceuticals, Inc. (REGN) | M.D., Ph.D. Board co-Chair, President and Chief Executive Officer | $1,811,995 | $7,004,069 |
| 2021 | Regeneron Pharmaceuticals, Inc. (REGN) | M.D., Ph.D. Board co-Chair, President and Chief Executive Officer | $1,767,800 | $6,470,514 |
| 2020 | Regeneron Pharmaceuticals, Inc. (REGN) | M.D., Ph.D. President and Chief Executive Officer | $1,480,119 | $135,350,121 |
| 2019 | Regeneron Pharmaceuticals, Inc. (REGN) | M.D., Ph.D. President and Chief Executive Officer | $1,377,100 | $21,455,117 |
| 2018 | Regeneron Pharmaceuticals, Inc. (REGN) | M.D., Ph.D. President and Chief Executive Officer | $1,330,500 | $26,520,555 |
| 2017 | Regeneron Pharmaceuticals, Inc. (REGN) | M.D., Ph.D. President and Chief Executive Officer | $1,285,500 | $26,508,058 |
